Medical Oncology

University of Utah   

Questions discussed in this category



If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...


Papers discussed in this category


J. Clin. Oncol., 2019 Oct 16

The Lancet. Oncology, 2018-02

Ann. Oncol.,

N Engl J Med, 2015 Jan 8

Lancet (London, England), 2013-03-09

The New England journal of medicine, 2018-07-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Annals of surgical oncology, 2009-06

Annals of surgical oncology, 2017-02

The Lancet. Oncology, 2013-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04

N Engl J Med, 2011 Oct 6

Lancet Oncol., 2012-01-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Breast Cancer Res Treat, 2009 Jun

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02

Trials, 2013 Aug 19

Ann. Oncol., 2012 Jun 06

Cancer,

The New England journal of medicine, 2019-02-14

Breast cancer research and treatment, 2014-11

The Lancet. Oncology, 2016-03